T
Tomas Bastys
Researcher at Max Planck Society
Publications - 5
Citations - 90
Tomas Bastys is an academic researcher from Max Planck Society. The author has contributed to research in topics: HIV-1 protease & Protein–protein interaction. The author has an hindex of 3, co-authored 5 publications receiving 62 citations. Previous affiliations of Tomas Bastys include Saarland University.
Papers
More filters
Journal ArticleDOI
Systematic discovery of linear binding motifs targeting an ancient protein interaction surface on MAP kinases
András Zeke,Tomas Bastys,Anita Alexa,Ágnes Garai,Bálint Mészáros,Klára Kirsch,Zsuzsanna Dosztányi,Olga V. Kalinina,Attila Reményi +8 more
TL;DR: It is proposed that short MAPK‐binding stretches are created in disordered protein segments through a variety of ways and they represent a major resource for ancient signaling enzymes to acquire new regulatory roles.
Journal ArticleDOI
Consistent Prediction of Mutation Effect on Drug Binding in HIV-1 Protease Using Alchemical Calculations
Tomas Bastys,Tomas Bastys,Vytautas Gapsys,Nadezhda Tsankova Doncheva,Nadezhda Tsankova Doncheva,Rolf Kaiser,Bert L. de Groot,Olga V. Kalinina +7 more
TL;DR: This study analyzes ten different protease-inhibitor complexes carrying major resistance-associated mutations (RAMs) G48V, I50V, and L90M using molecular dynamics simulations and demonstrates that alchemical free energy calculations can consistently predict the effect of mutations on drug binding.
Journal ArticleDOI
Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
Tomas Bastys,Tomas Bastys,Vytautas Gapsys,Hauke Walter,Eva Heger,Nadezhda Tsankova Doncheva,Nadezhda Tsankova Doncheva,Rolf Kaiser,Bert L. de Groot,Olga V. Kalinina,Olga V. Kalinina +10 more
TL;DR: Estimating the effect of both binding pocket and distant mutations on inhibitor binding free energy using alchemical calculations can reproduce their effect on the experimentally measured I C 50 values indicates valuable insights on interplay between primary and background mutations and mechanisms how they affect inhibitor binding.
Peer ReviewDOI
Author response for "A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance"
Journal ArticleDOI
A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
TL;DR: It is found that Y823D affects the protein dynamics differently: in the active state, the mutation increases the protein stability, whereas in the inactive state it induces local destabilization, thus shifting the dynamic equilibrium towards the activeState, altering the communication between distant regulatory regions.